← Back to Search

AutoTutor (PsyGist) for Psychosis

Phase 1
Waitlist Available
Led By Lawrence Yang, PhD
Research Sponsored by New York University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, immediately post-intervention, up to 30 minutes
Awards & highlights

Study Summary

This trial aims to develop two clinical tools to help high-risk youth make healthy choices by using a genetic malleability framing.

Eligible Conditions
  • Psychosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, immediately post-intervention, up to 30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, immediately post-intervention, up to 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in Intention to Use Treatment
Change From Baseline in Perceived Treatment Efficacy
Secondary outcome measures
Anticipated Rejection From Others Due to Genetic Risk for Psychosis Development
Change From Baseline in Self-Stigma About Genetic Risk for Psychosis Development
Change in Anticipated Discrimination From Others Due to Genetic Risk for Psychosis Development

Trial Design

2Treatment groups
Experimental Treatment
Group I: Clinician ManualExperimental Treatment1 Intervention
Participants in the Clinician Manual arm will be introduced to a trained clinician and will complete one 60-minute session covering equivalent topics addressed in the PsyGist program. The manual will consist of: (1) a section exploring the youth's causal model for their high-risk state; (2) individualization per their causal model; and (3) tutorials that convey the main concepts of genetic malleability. Clinicians will assess individual causal models via discussion with CHR youth about their at- risk state. Individualization of genetic framing will occur using youths' causal models and will fall into 1 of 3 categories (per PsyGist): 'primarily genetic', 'primarily environmental' or 'combined'.
Group II: AutoTutor (PsyGist)Experimental Treatment1 Intervention
AutoTutor is an intelligent system that simulates talking with a human tutor. Our AutoTutor, called PsyGist, has 3 parts: (1) assessment of the youth's causal model for their high-risk state; (2) an individualized 'pre-tutorial' vignette matched to their causal model; (3) a 'tutorial' presenting the 'genetic malleability' framing. PsyGist will guide participants through its three components.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PsyGist and Clinician Manual
2020
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

New York State Psychiatric InstituteOTHER
475 Previous Clinical Trials
153,630 Total Patients Enrolled
7 Trials studying Psychosis
950 Patients Enrolled for Psychosis
New York UniversityLead Sponsor
227 Previous Clinical Trials
312,944 Total Patients Enrolled
2 Trials studying Psychosis
424 Patients Enrolled for Psychosis
Lawrence Yang, PhDPrincipal InvestigatorNew York University
1 Previous Clinical Trials
360 Total Patients Enrolled
~6 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top